{
    "clinical_study": {
        "@rank": "158047", 
        "acronym": "PCM304", 
        "arm_group": {
            "arm_group_label": "TOOKAD\u00ae Soluble", 
            "arm_group_type": "Experimental", 
            "description": "TOOKAD\u00ae Soluble, lyophilized formulation,given at a dose of 4 mg/kg."
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to confirm the Efficacy and the Quality of Life after TOOKAD\u00ae\n      Soluble VTP in localized prostate cancer patients."
        }, 
        "brief_title": "Efficacy and Quality of Life After TOOKAD\u00ae Soluble Vascular Targeted Photodynamic Therapy for Localized Prostate Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study is designed as a multicenter, single-arm, open label, 12 months follow-up clinical\n      trial. Men with localized prostate cancer will be treated with TOOKAD\u00ae Soluble VTP under\n      general anesthesia.\n\n      Patients will be followed-up for 12 months with patient questionnaires on QoL, erectile and\n      urinary functions, clinical evaluation with study visits at 1, 3, 6 and 12 months , Prostate\n      Specific Antigen(PSA) testing at 3, 6 and 12 months. In addition, they will have biopsy at 6\n      months (\u00b1 2) and 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven localized prostate carcinoma diagnosed using prostate biopsy\n             showing:\n\n               -  Gleason 3+3 prostate\n\n               -  Gleason 3+4 prostate adenocarcinoma is acceptable provided it is not  present in\n                  more than 2 cores and no more than 50% cancer in any core.\n\n          -  Clinical stage up to cT2a - N0/Nx - M0/Mx.\n\n          -  Prostate volume \u2265 25 cc and \u2264 70 cc.\n\n          -  Male subjects aged 18 years or older.\n\n          -  Signed Informed Consent Form by the patient.\n\n        Exclusion Criteria:\n\n          -  Unwillingness to accept the treatment.\n\n          -  Any prior or current treatment for prostate cancer, including surgery, radiation\n             therapy (external or brachytherapy)or chemotherapy.\n\n          -  Any surgical intervention for benign prostatic hypertrophy.\n\n          -  Any condition or history of illness or surgery that may pose an additional risk to\n             men undergoing the VTP procedure.\n\n          -  Life expectancy less than 10 years.\n\n          -  Participation in another clinical study involving an investigational product within 1\n             month before study entry.\n\n          -  Subject unable to understand the patient's informed consent document, to give consent\n             voluntarily or to complete the study tasks, especially unable to understand and\n             fulfill the health-related QoL questionnaire. Subject in custody and or in residence\n             in a nursing home or rehabilitation facility."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875393", 
            "org_study_id": "CLIN1201 PCM304"
        }, 
        "intervention": {
            "arm_group_label": "TOOKAD\u00ae Soluble", 
            "description": "The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD\u00ae Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.", 
            "intervention_name": "TOOKAD\u00ae Soluble", 
            "intervention_type": "Drug", 
            "other_name": "WST11"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostatic Disease", 
            "Genital Neoplasm,male", 
            "Urogenital neoplasm", 
            "Genital disease,male", 
            "Male urogenital disease", 
            "Neoplasms", 
            "Neoplasms by site", 
            "Prostatic neoplasm", 
            "Carcinoma"
        ], 
        "lastchanged_date": "June 7, 2013", 
        "location": [
            {
                "contact": {
                    "email": "arturo_doc@yahoo.com", 
                    "last_name": "Jose Arturo Ramirez, Dr", 
                    "phone": "(55) 5850-1011", 
                    "phone_ext": "76216"
                }, 
                "facility": {
                    "address": {
                        "city": "Del Tlalpan", 
                        "country": "Mexico", 
                        "zip": "14250"
                    }, 
                    "name": "Hospital Dr. Ajusco Medio"
                }, 
                "investigator": {
                    "last_name": "Jose Arturo Ramirez, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "arurol@hotmail.com", 
                    "last_name": "Jose Arturo Rodrigez Rivera, Dr", 
                    "phone": "(33)3587-9090"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico DF", 
                        "country": "Mexico", 
                        "zip": "13278"
                    }, 
                    "name": "Hospital General Tlahuac"
                }, 
                "investigator": {
                    "last_name": "Jose Arturo Rodrigez Rivera, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dr_memm@hotmail.com", 
                    "last_name": "Mary Lol Ve Mendoza Medina, Dr", 
                    "phone": "01 (55) 5850-1011 (76102)"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico DF", 
                        "country": "Mexico", 
                        "zip": "13278"
                    }, 
                    "name": "Hospital General Tlahuac"
                }, 
                "investigator": {
                    "last_name": "Mary Lol Ve Mendoza Medina, Dr", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study of the Efficacy and Quality of Life After TOOKAD\u00ae Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer", 
        "overall_official": [
            {
                "affiliation": "Hospital General Tlahuac", 
                "last_name": "Jose Arturo Rodriguez Rivera, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Dr. Ajusco Medio", 
                "last_name": "Jose Arturo Ramirez, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital General Tlahuac", 
                "last_name": "Mary Lol Ve Mendoza Medina, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Mexico: Federal Commission for Sanitary Risks Protection", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Brazil: National Health Surveillance Agency", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Peru: Instituto Nacional de Salud", 
                "Panama: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with a negative biopsy.", 
            "measure": "To confirm that a significant proportion of patients will be prostate cancer free on the biopsy.", 
            "safety_issue": "No", 
            "time_frame": "Month 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients' reported outcome measures (PROMs) impairment: urinary symptoms using IPSS and erectile functions using IIEF. Quality of life using EQ5D will also be described", 
                "measure": "Changes in urinary and erectile functions and their potential impact on quality of life using International Prostate Symptom Score (IPSS),  International Index of Erectile Function (IIEF) and the General quality of life (EQ5D) questionnaires.", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, 1, 3, 6 and 12 months after completing treatment"
            }, 
            {
                "description": "Adverse event reporting.", 
                "measure": "The rate of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Screening-Month 12"
            }, 
            {
                "description": "Total length of cancer present in all cores taken in any given biopsy session", 
                "measure": "The overall cancer burden in the prostate determined by biopsy as compared to baseline.", 
                "safety_issue": "Yes", 
                "time_frame": "Month 12"
            }, 
            {
                "description": "Severe prostate cancer related events: cancer extension to T3, metastasis or prostate cancer-related death.", 
                "measure": "The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death", 
                "safety_issue": "Yes", 
                "time_frame": "Screening-Month 12"
            }
        ], 
        "source": "Steba Biotech S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Steba Biotech S.A.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}